Polartechnics forecasts profit
Tuesday, 25 November, 2008
Sydney-based diagnostics company Polartechnics has forecast a massive boost in revenue for 2010 after signing a series of contracts with Chinese distributor Unisplendour.
Chairman Robert Hunter told Polartechnics’ AGM today that the company expects to become profitable in 2010 on the basis of the contracts, involving the supply of 500 TruScreen units next year.
TruScreen is Polartechnics’ lead product, a point of care detection device for cervical cancer.
The company expects sales of the device to leap from $3 million next year to $52 million in 2010, and to $121 million in 2011.
It has also forecast revenue from its CerviScreen product, a self-administered human papillomavirus detection kit, to reach $30 million in 2011.
The company has had a chequered history but has recently signed an encouraging local joint venture and says it has solved production issues with its Chinese manufacturer.
An analysis by Phillip Capital Australia, which has provided capital raising and advisory services to Polartechnics, forecasts a profit after tax of $11 million in 2010 and almost $50 million in 2011.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
